Physician profile
Raymond Chan
NPI 1477741981
$25,088.49
in general payments reported to CMS, 2019-2025
40 companies · $4,460 in 2025
The $4,460 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,770 · 2020: $958 · 2021: $2,822 · 2022: $3,179 · 2023: $3,976 · 2024: $5,924 · 2025: $4,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,360.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,565.15 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $2,959.04 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $2,932.06 | 2019-2025 | Creon, Linzess, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,639.49 | 2020-2025 | Jardiance, Ofev, Stiolto Respimat |
| Amgen INC. | $2,087.24 | 2019-2025 | Repatha, Evenity, Repatha |
| Gilead Sciences, INC. | $1,461.30 | 2019-2025 | Vemlidy, Livdelzi |
| Novo Nordisk INC | $1,413.45 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amarin Pharma, INC. | $891.37 | 2019-2023 | |
| Lilly USA, LLC | $661.54 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $612.82 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $570.84 | 2021-2025 | |
| Insmed, INC. | $434.41 | 2019-2023 | Arikayce |
| Phathom Pharmaceuticals, INC. | $423.75 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $420.24 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $408.77 | 2023-2025 | Cologuard Collection Kit |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.